Author Archives: admin

Visiongain Report Offers Transformative Insights on the $3.2bn Protein Expression Market – PRNewswire

LONDON, Nov. 25, 2019 /PRNewswire/ -- The global protein expression market is estimated at $1.8bn in 2018. Visiongain estimated that the prokaryotic expression system accounted for 40.0% of the global protein expression market.

How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 201-page report you will receive 70 tables and 115 figures all unavailable elsewhere.

The 201-page Visiongain report provides clear detailed insight into the global protein expression market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-protein-expression-market-forecast-to-2029/#download_sampe_div

Report Scope

Global Protein Expression Market forecaststo 2029

Global Protein Expression Market forecaststo 2029by Expression System: Cell-free Expression System Prokaryotic/ Bacterial Expression System Yeast Cell Expression Systems Algal-based Expression Systems Insect Cell Expression Systems Mammalian Cell Expression Systems

Global Protein Expression Market forecasts to 2029by Product & Services: Reagents Expression Vectors Competent Cells Instruments Services

Global Protein Expression Market forecasts to 2029by Application: Therapeutic Applications Industrial Application Research Application

Global Protein Expression Market forecaststo 2029by End-User: Pharmaceutical and Biotechnology Companies Academic Research Institutes Contract Research Organizations (CROs)

Global Protein Expression Market forecaststo 2029by National Market: North America: US, Canada EU: Germany, France, UK, Italy, Spain Asia: Japan, China, India

Assessment of selectedleading companies that hold major market shares in the protein expression industry: Agilent Technologies Bio-Rad Technologies EMD Milipore New England Biolabs, Inc. Oxford Expression Technologies, Ltd. Promega Corporation Qiagen NV Takara Bio, Inc. Thermo Fisher Scientific, Inc.

Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the protein expression market. Moreover, this report discussesfactors that drive and restrain the protein expression market.

Key Questions Answered by This Report: What is the current size of the protein expression market? How much will this market be worth from 2019-2029? What will be the main drivers and restraints for this market? What are the different segments of the protein expression market? How much will each of these segments be worth during 2019-2029 and how will their market shares change during this period? What are the largest national protein expression markets? How much will these markets be worth from 2019-2029? How will the emerging markets affect the market shares of the mature markets? What are the most prominent companies in the market? What products and services do they offer, and what are the main features and advantages of them? What are the main trends affecting the market? What technologies will increase in prominence between 2019 and 2029? What are the advantages of these technologies? What are the main strengths, weaknesses, opportunities and threats for the market? What are the social, technological, economic and political factors affecting the market?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-protein-expression-market-forecast-to-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

Abgenex Agilent Technologies Inc.Anthem BiosciencesAstraZenecaBayerBio-Rad TechnologiesBiotechnology Industry Research Assistance Council BioTek InstrumentsBrammer BioBristol-Myers Squibb Cancer Research UK Centers for Disease Control and Prevention Clontech Laboratories, Inc. Department of Biotechnology EMD MilliporeGIMDx, Inc. HD Biosciences Co., Ltd.Icagen, Inc. IncellDx, IncInnoCore PharmaceuticalsInSphero AG Institute for Molecular Medicine Finland JanssenLabcyte Inc.LikardaLuxcel Biosciences LtdMerckMerck & Co., IncNew England Biolabs Inc.Novo Nordisk Foundation Center for Biosustainability On Target Co., Ltd. OriGeneOxford Expression Technologies LtdPharmaceutical Research and Manufacturers of America Promega CorporationQiagen NVSanofiSciGenomSigma-Aldrich CorporationSino BiologicalsTakara Bio Inc.Takeda Pharmaceutical Company Technical University of Denmark Thermo Fisher Scientific Inc.UCBWaferGen Bio-systems, Inc. World Health Organization

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Immunochemistry Reagents, Analyzers and Test Kits Market 2019-2029

Pharmaceutical Contract Manufacturing Market 2019-2029

Global Medical Device Contract Manufacturing Market Forecast 2019-2029

3D Printing for Healthcare Market Report 2019-2029

Global Stem Cell Technologies and Applications Market 2019-2029

SOURCE Visiongain

Go here to read the rest:
Visiongain Report Offers Transformative Insights on the $3.2bn Protein Expression Market - PRNewswire

Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions – Business Wire

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (Immune-Onc), a privately held cancer immunotherapy company, announced today the addition of several industry veterans to its executive team and advisory boards and the promotion of An Song, Ph.D. to Chief Scientific Officer from Senior Vice President of Development Sciences. Dr. Paul Woodard joins Immune-Onc from Bellicum Pharmaceuticals, Inc. where he most recently served as Senior Vice President, Clinical and Medical Affairs.

We are thrilled to add such seasoned and strategic individuals to the executive and advisory teams guiding Immune-Onc through its next phase of growth as a clinical stage company, said Charlene Liao, Ph.D., Co-founder and Chief Executive Officer of Immune-Onc. As our Chief Medical Officer, Paul brings the right combination of deep expertise in oncology paired with proven strategic leadership and experience building teams and functions in a startup environment. The appointment of An to Chief Scientific Officer is a reflection of the contributions she has already made to the company in her current role and a recognition of the value that her experience will bring in guiding the translation of our science into development.

I cant imagine a more exciting time to join Immune-Onc, said Dr. Woodard. I was first drawn to the novel science underlying the portfolio. As I learned more about Immune-Onc and their authentic passion for improving patient lives, it became clear to me that this was a company that I wanted to contribute to in a meaningful way with the goal of bringing much needed new treatment options to people with hard-to-treat cancers like acute myeloid leukemia.

About Paul Woodard, M.D.

As Chief Medical Officer, Dr. Woodard will be responsible for clinical leadership and medical oversight of the Immune-Onc portfolio. These activities will include review and input of IND submissions, clinical protocol development and medical oversight of Immune-Onc trials, and oversight of internal and external clinical development, biometrics, safety, and regulatory functions and compliance.

Dr. Woodard has an extensive hematology and oncology background gained in academia and industry. His academic experience focused on pediatric hematopoietic stem cell transplantation and hematologic disorders at world-renowned institutions, including St. Jude Childrens Research Hospital, University of California, San Francisco, and Childrens Hospital, Los Angeles. In addition to patient care, at St. Jude, Dr. Woodard was responsible for Phase 1/2 trials in pediatric hematopoietic stem cell transplantation for malignant and non-malignant disorders.

Prior to joining Immune-Onc, Dr. Woodard worked on a wide range of drug development projects in solid tumors, hematologic malignancies, and non-malignant hematologic disorders. At Exelixis, Dr. Woodard worked on small molecule tyrosine kinase inhibitors for solid tumors. At Amgen, Dr. Woodard was the global development leader for Nplate (romiplostim) in immune thrombocytopenia and myelodysplastic syndromes. At Genentech, Dr. Woodard was the global development team leader for Tecentriq (atezolizumab) in hematologic malignancies and was an integral team member for the development of Tecentriq combinations in solid tumors (including triple negative breast cancer) and hematologic malignancies. At Bellicum, Dr. Woodard was the Senior Vice President of Clinical and Medical Affairs, with oversight of the companys cellular therapy portfolio and clinical trials in hematologic malignancies and solid tumors.

Dr. Woodard earned his medical degree at the University of North Carolina and completed his residency at the University of Virginia and fellowships in pediatric hematology-oncology at the University of North Carolina and in pediatric blood and marrow transplantation at the University of Minnesota.

About An Song, Ph.D.

Dr. Song joined Immune-Onc in July 2018 as Senior Vice President of Development Sciences. In the newly created role of Chief Scientific Officer, Dr. Song will have overall accountability for translational development of Immune-Oncs portfolio and strategic oversight of research and antibody engineering.

Dr. Song is a translational scientist with 22 years of experience across basic research and drug development in oncology, autoimmunity, metabolic, infectious, and neurodegenerative diseases. Dr. Song joins Immune-Onc from Genentech where, as a Senior Director in BioAnalytical Sciences, she led the Assay Development and Technology group for the companys large molecule portfolio globally and was a member of numerous scientific review bodies within the Genentech Research and Early Development (gRED) organization. During her 16-year tenure at Genentech, Dr. Song contributed to, and oversaw 40+ IND/CTA and BLA/MAA regulatory filings for products including Rituxan, Avastin, Herceptin, Lucentis, Kadcyla and Tecentriq. In addition, Dr. Song played a significant role in the development and approval of Ocrevus.

Dr. Song received her Ph.D. in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in immunology, followed by a faculty position as Assistant Professor (Research) at Stanford University. As an active member of the American Association of Pharmaceutical Scientists (AAPS), Dr. Song has served as an executive member of the Biotech Section and chair of the Therapeutic Product Immunogenicity (TPI) Focus Group/Community.

BOARD APPOINTMENTS

In addition, Immune-Onc bolstered its cadre of advisors with the appointment of Zhengbin (Bing) Yao, Ph.D. to its Board of Directors and Gregory Cosma, Ph.D. to its Scientific Advisory Board. Both Bing and Greg bring significant experience in helping early-stage companies navigate the complexity of drug development, commented Dr. Liao. Bing and Gregs perspectives are invaluable in supporting Immune-Onc in our mission to deliver transformative therapies to cancer patients.

About Zhengbin (Bing) Yao, Ph.D.

Dr. Yao has more than 20 years of experience in the biopharmaceutical industry, with a proven track record of successfully leading the discovery and development of multiple biotherapeutics. Dr. Yao is currently Chairman of the Board and CEO of Viela Bio. Prior to this role, he was Senior Vice President, Head of Respiratory, Inflammation and Autoimmune iMED at MedImmune/AstraZeneca. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications. Previously, Dr. Yao also served as Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca, as well as CEO for WuXi-MedImmune Joint Venture. Dr. Yao joined MedImmune in 2010 from Genentech, where he was the Head of Project Team Leaders for Immunology, Infectious Diseases, Neuroscience, and Metabolic Disease. He was Vice President and Head of Research for Tanox, before the company was acquired by Genentech in 2007. Dr. Yao also held several positions of increasing responsibility at Aventis and Amgen and currently serves on the Board of Directors for NexImmune. Dr. Yao received his Ph.D. in Microbiology and Immunology from the University of Iowa, followed by postdoctoral work at Immunex.

About Gregory Cosma, Ph.D.

As a former executive at Genentech and Bristol-Myers Squibb, Dr. Cosma has a long track record of success leading companies in translating science into approved therapies. As Vice President of Research and Early Development at Genentech from 2010-2019, Dr. Cosma led the Safety Assessment organization comprising Toxicology, Pathology, Product Quality and Occupational Toxicology and Nonclinical Operations. He also chaired the Genentech Development Review Committee (DRC), overseeing nonclinical development of the Genentech pipeline from Research to First-in-Human studies. While at Bristol-Myers Squibb from 2003-2010, Dr. Cosma held roles as the Executive Director for Drug Safety Evaluation and as the Therapeutic Area Head for Metabolic Diseases. Prior to these roles, Dr. Cosma was a Research Fellow at Pharmacia-Pfizer and an assistant professor in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. Dr. Cosma earned his doctorate in Pharmacology/Toxicology at the University of Kansas.

ABOUT IMMUNE-ONC THERAPEUTICS, INC.

Immune-Onc Therapeutics, Inc. (Immune-Onc) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit http://www.immune-onc.com.

Follow this link:
Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions - Business Wire

A sound theoretical mechanism and clinical indication are not enoughthe case of Platelet Rich Plasma for Achilles tendon ruptures – The BMJ – The BMJ

A global industry has grown around using platelet rich plasma (PRP) in sports medicine. Its appeal has been heightened by use in high profile athletes. PRP has evolved over millennia. As natures most refined healing elixir of minute vessels packed with bioactive proteins, it stood every chance of being that new accelerant of tissue healing.

To produce PRP, the patients own blood is processed, usually in a specialised centrifuge, to produce a solution containing a supraphysiological concentration of platelets. But where does it lie in the spectrum between another fashionable application and a proven novel regenerative therapy? We set out to sift the evidence from the enthusiasm with an open mind, and to place some robust research quality markers that would allow proper critique.

Our 2016 paper in The BMJ discussed the uncertainties in this area, and looked at how effective platelet rich plasma injections are in treating musculoskeletal soft tissue injuries. At the time there had been 29 randomised controlled trials, but it was difficult to draw clear conclusions about efficacy, because of PRP use in heterogeneous musculoskeletal conditions, underpowered studies, and poor reporting. [1]

Furthermore, few trials included an analysis of PRP content or quality, yet PRP had been adopted widely in clinical practice. Many commercially available PRP preparation devices had US Food and Drug Administration approval based on device performance and safety, but not clinical efficacy. [2] However, animal and cellular research was providing some encouraging evidence in support of a theoretical mechanism and potential effect. [3]

It was because of the latter that we embarked upon the PATH-2 trial to investigate the efficacy of PRP. We identified acute Achilles tendon rupture as a suitable human injury to study, as it is common and patients often experience a frustrating recovery, due to slow tissue healing and recovery of muscle function. The case for robust evaluation was clear, however the complexity and cost of a randomised controlled trial were significant. We first conducted a pilot with embedded mechanistic studies to address the limitations of previous trials, then recruited to the largest trial of PRP to date in 19 UK hospitals. To standardise PRP, we provided the same specialist centrifuge to each hospital, standard operating procedures and training in blood sample handling, and tested all blood and PRP samples at a central laboratory. Recruiting participants in busy trauma clinics, and handling the masking of the PRP or dry needle injection were some of the challenges. For our findings to be unequivocal the primary outcome needed to be an instrumented muscle performance test by a blinded assessor; that ensured objective alongside patient-reported outcomes.

The results of the PATH-2 trial are now published in The BMJ, and show that when subjected to robust evaluation, there is no evidence of patient benefit from injecting high quality PRP for acute Achilles tendon ruptures.

It took years of development, trialling, and evaluation, to deliver this negative finding. Some may think that this was a misplaced effort and resources. But safety and efficacy are paramount as no intervention is without risk or cost, even if autologous. This may not be the end of the PRP story. We assumed natures recipe of bioactive proteins released from activated platelets was the ideal, but perhaps some ingredients have more potency than others. There is a clear sense, however, that the many other current musculoskeletal PRP applications now need to be subjected to similar evaluation. There is also a wider message about adopting innovations into practice and the balance with robust clinical trial evaluation. Enthusiasm for using promising technologies and a strong theoretical justification from pre-clinical research are insufficient. This is especially important where new interventions are not subjected to the same regulations as new medicines.

David J Keene, NIHR Postdoctoral Research Fellow, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. @davidkeenePT

Keith Willett, Professor of Orthopaedic Trauma Surgery, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Competing interests: See research paper.

References:

View post:
A sound theoretical mechanism and clinical indication are not enoughthe case of Platelet Rich Plasma for Achilles tendon ruptures - The BMJ - The BMJ

Joint Pain Injections Market Research : Key Companies Profile with Sales, Revenue, Price and Competitive Situation Analysis | Allergan Plc., Pfizer…

Market Synopsis:A New exploration report titled Global Joint Pain Injections market effectively displays the total situation of the global and an individual investigation of the different regional segments. It gives, any place pertinent and important, specialized information of products, and reveals helpful insight into expected business creation dates and current R&D status. This report will help the viewer in Better Decision Making.

For Better Understanding, Download Free Sample PDF Brochure of Joint Pain Injections Market Research Report @https://marketresearch.biz/report/joint-pain-injections-market/request-sample

MarketResearch.Biz offers 2019report on Global Joint Pain Injections Market that assesses industry development drifts through chronicled information and appraisals future possibilities dependent on exhaustive research. The report widely gives the piece of the overall industry, development, patterns, and figures for the period 2019-2028.Joint Pain Injections Market investigate report completely clarifies every single viewpoint identified with the Joint Pain Injections Market, which encourages the reports reader to think about and assess the up-coming business sector drift and execute the logical data to advance the business.The development pattern anticipated because of intensive assessment offers inside and out data in regards to the Joint Pain Injections Market. A pathway of improvement is offered by the market to the few associated systems of organizations under it, which incorporate various firms, enterprises, associations, sellers, wholesalers, and nearby producers as well. All the key Joint Pain Injections Market players contend with one another by offering better products and administrations at a sensible cost so as to snatch huge share at the regional and global level market.

The report also provides a competitor analysis of Key Trends & advanced technologies. The Joint Pain Injections (Thousands Units) and Revenue (Million USD) Market Split by Key players such as Allergan Plc., Pfizer Inc, Sanofi, Anika Therapeutics Inc, Ferring B.V., Bioventus LLC, Flexion Therapeutics Inc, Zimmer Biomet Holdings Inc, Seikagaku Corporation, Chugai Pharmaceutical Co Ltd

Joint Pain Injections Market Report segments Cover:

Segmentation by Injection type:

Corticosteroid InjectionsHyaluronic Acid InjectionsOthers (include, Platelet-rich plasma (PRP), Placental tissue matrix (PTM), etc.)Segmentation by joint type:

Knee & AnkleHip JointShoulder & ElbowFacet Joints of the SpineOthers (include, Ball and socket, etc.)Segmentation by end-user:

Hospital PharmaciesRetail PharmaciesOnline Pharmacies

Inquire/Speak To Expert for Further Detailed Information About Joint Pain Injections Report:https://marketresearch.biz/report/joint-pain-injections-market/#inquiry

Joint Pain Injections Market Impressive Report Offerings:

1.It gives a development considering the point of view on various components driving or limiting Joint Pain Injections Market development

2.It helps in tolerating the significant item fragments and their future

3.It conveys stick point investigation of fluctuating challenge elements and keeps you in front of Joint Pain Injections Market contenders

4.It helps in settling on perceptive expert choices by having intensive bits of knowledge of the market and by making inside and out an investigation of market fragments

5.It helps in local promoting type investigation, global exchange type examination, and inventory network investigation;

6. It comprehends Joint Pain Injections fabricating cost structure, crude material, and providers, producing process, industry chain structure;

7.It serves to standpoint limit examination (organization portion), deals investigation (organization fragment), and deals value examination

8.It gives a verifiable conjecture surveyed based on how the Joint Pain Injections Market is anticipated to develop

Share Your Questions Here For More Details On this Report or Customizations As Per Your Need:https://marketresearch.biz/report/joint-pain-injections-market/#request-for-customization

Get in touch with Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue, Suite 300 New York City, NY 10170,

United States

Tel:+ 1-347-826-1876

Website:https://marketresearch.biz/

Continue reading here:
Joint Pain Injections Market Research : Key Companies Profile with Sales, Revenue, Price and Competitive Situation Analysis | Allergan Plc., Pfizer...

Global Joint Pain Injections Market Key Drivers and Opportunities Till 2028 – True Version

According to the report, the Joint Pain Injections Market: Industry Perspective, Comprehensive Analysis, and Forecast, 2019-2028 share of global Joint Pain Injections industry is dominate by companies like Vendors Covered, Vendor Classification, Market Positioning Of Vendors. Some of Major Eminent Key Players areAllergan Plc., Pfizer Inc, Sanofi, Anika Therapeutics Inc, Ferring B.V., Bioventus LLC, Flexion Therapeutics Inc, Zimmer Biomet Holdings Inc, Seikagaku Corporation, Chugai Pharmaceutical Co Ltd

Furthermore, the report offers an extensive standpoint of current patterns and new item dispatch in the worldwide market. Highlighting worldwide and provincial information and overdriving key players profiles, this report serves a definitive manual for investigating openings in the Joint Pain Injections business all-inclusive. The creator of the report has utilized basic language and uncomplicated factual figures that contained intensive data and complete data on the worldwide market. The report gives market players helpful data and proposes result-arranged strategies to increase an aggressive edge in the Joint Pain Injections market.

For Better Understanding, Download Free Sample PDF Brochure of Joint Pain Injections Market Research Report @https://marketresearch.biz/report/joint-pain-injections-market/request-sample

The report offers the Joint Pain Injections business development rate, size, and figures at the worldwide level likewise concerning the geographic territories. The industry-changing components for the market portions are investigated in this report. The report covers the development components of the overall market dependent on end-clients. Likewise, this report talks about the key drivers affecting market development, openings, the difficulties, and the dangers looked by key producers and the market in general. It likewise breaks down key rising patterns and their effect on present and future advancement.

Segments of Joint Pain Injections Market by :

Segmentation by Injection type:

Corticosteroid InjectionsHyaluronic Acid InjectionsOthers (include, Platelet-rich plasma (PRP), Placental tissue matrix (PTM), etc.)Segmentation by joint type:

Knee & AnkleHip JointShoulder & ElbowFacet Joints of the SpineOthers (include, Ball and socket, etc.)Segmentation by end-user:

Hospital PharmaciesRetail PharmaciesOnline Pharmacies

The study objectives of this report are:

Analyzing the outlook of the market with recent trends and SWOT analysis.

Joint Pain Injections Market dynamics scenario, along with growth opportunities of the market in the years to come.

Joint Pain Injections market segmentation analysis including quantitative and qualitative research incorporating the impact of economic and non-economic aspects.

Regional and country-level Joint Pain Injections analysis integrating the demand and supply forces that are influencing the growth.

Joint Pain Injections market value (USD Million) and volume (Units Million) data for each segment and sub-segment.

Competitive landscape affecting major players market share, as well as new projects and approaches that players have embraced over the past five years.

Comprehensive company profiles covering important economic data, product offerings, latest trends, SWOT analysis and strategies used by significant players in the market.

Any Questions? Fill Free To Enquire Here. Well Put You On The Right Path:https://marketresearch.biz/report/joint-pain-injections-market/#inquiry

The Joint Pain Injections Market report answers the questions below:

Who will be the target customers for Joint Pain Injections Market for the forecast period, 2019 to 2028?

Where are most buyers located?

What are the latest trends in the Joint Pain Injections Market? How will they impact the future of the industry during the estimated period?

Is the Joint Pain Injections Market share growing fast or declining?

Is the market large enough for the major vendors to expand their business and increase the customer base?

How many potential customers are there in a particular region?

Share Your Questions Here For More Details On this Report or Customizations As Per Your Need:https://marketresearch.biz/report/joint-pain-injections-market/#request-for-customization

Contact Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue, Suite 300 New York City, NY 10170,

United States

Tel:+ 1-347-826-1876

Website:https://marketresearch.biz/

Follow this link:
Global Joint Pain Injections Market Key Drivers and Opportunities Till 2028 - True Version

Father-Son Team Creates Beauty and Healing – Atlanta Jewish Times

Every father should remember that one day his son will follow his example instead of his advice. Charles F. Kettering, engineer-inventor

Walking in a fathers shadow ranges from being a challenge to being a prince. The latter is the case of Dr. Farzad Nahai, who relished the path of dad Dr. Foad Nahai, a well-respected professor and practitioner. Learn how their paths unfolded, one working with Navajo Indians and landing as the sole plastic surgeon in a dermatology group, the other a sought after worldwide plastic surgeon, author and speaker who has wielded a scalpel for 44 years.

All-American son Farzad Nahai graduated from the Westminster Schools. Math and science came easily to him, which put him on the path to medical school. He recalled, Dad was my hero. Back then, there were no computers, so at home I looked at his medical slides and over his shoulder in the operating room. Good thing was that I was not bothered by blood! During the summers, I was a scrub tech. He eventually sought out plastic surgery as an opportunity to be thoughtful, creative and solution-oriented.

Get The AJT Newsletter by email and never miss our top storiesFree Sign Up

Father and son practiced together for eight years, before the junior Nahai joined another specialty practice, MetroDerm, P.C., as the only plastic surgeon among 10 dermatologists.

Dr. Farzad Nahai enjoys following in his fathers footsteps.

About 70 percent of his practice is elective versus procedures such as skin cancer reconstruction. I practice the full spectrum of plastic surgery: faces, breasts, full bodies, and injectables. I also have fond memories of walking the hall with Dad discussing different surgeries and What should we do about that nose?

Earlier in his training, Farzad did something very unique. During medical school, he answered a random letter from the government to help Native Americans in Montana. I loved giving back and would do it all over again. Then the year between his general residency and specialization, he packed up for Shiprock, N.M., for a full year helping Navajos by performing general surgery, lumps and bumps and concurrently getting meaningful experience.

For whats new on the horizon, Farzad said, Theres a push for innovation in less invasive procedures in the filler category. Some of the newer ones are ultrasonic therapy, microneedling, and ThermiTight. PRP (platelet-rich plasma) are injections that can repair aged skin and stimulate hair growth (in the case of hair loss) and are becoming more common.

A lot of my patients are women in their 50s, 60s and even 70s who want to look refreshed. They want the outside to match the inside.

His father, Foad, was born in Tehran, where his family was in the insurance business. He later grew up in England. After medical school at the University of Bristol in the U.K., he came in 1970 to the United States and never left. He is known as one of the most respected fathers of plastic surgery and a prominent lecturer at medical schools and symposia, and is now publishing his third edition of the reference-textbook The Art of Aesthetic Surgery while serving as Jurkiewicz Chair in Plastic Surgery and professor at Emory University School of Medicine. In total, he has authored 14 books and is currently editor-inchief of Aesthetic Surgery Journal.

Among his current contributions to scientific advances is the reduction of the length of post-surgical scarring using endoscopy.

Dr. Foad Nahai is a prolific author and Emory University medical school professor.

Foads practice now is primarily elective surgery.

His earlier career included reattaching limbs for replantation instead of transplantation. He noted, Forty years ago the rejection medications were not reliable like they are today.

Starting from a baseline, one might ask, Do I need a facelift?

Foads response: Its not a matter of age. One 50-year-old might look 65, another 50-year-old may appear to be 40. Part of this is genetics. The other part is a healthy lifestyle, not smoking, limited exposure to the sun. Those with a healthy lifestyle tend to age more slowly. It might be surprising to note that patients as young as 40 come to Dr. Nahai for this determination. Injectables (fillers, Botox, etc.) are safe and appropriate for those not yet candidates for surgery. But in the long run, surgery will produce better results and be more cost-effective.

When asked what gives him the most pride, he touts his 50-year marriage and raising skilled and caring children. Professionally, I have trained over 100 surgeons who are both ethical and competent. So I would say training others to do well is the best reward.

Sentimentally I was always secretly hoping that Farzad would choose to follow me in a medical career, but I did not push him. I am lucky; it just came naturally to him.

Read more:
Father-Son Team Creates Beauty and Healing - Atlanta Jewish Times

Many stem cell clinics promise unapproved treatments: How to stay safe – NBC News

Google has cracked down on pervasive, predatory ads promoting sketchy medical treatments a move that could affect many of the hundreds of stem cell treatments advertised online.

At the end of October, the internet giant stopped accepting ads for unproven or experimental medical techniques, according to a statement from the company. Google is taking this step after seeing a rise in bad actors offering deceptive and untested treatments, the company said.

Stem cells came up this week during the senate confirmation hearing for the next head of the Food and Drug Administration on Wednesday.

"FDA has taken enforcement action, which it should, against stem cell clinics and manufacturers that might be misleading people," Sen. Lamar Alexander (R-Tenn.) said. "On the other hand, we have diabetes advocates who say regenerative medicine may restore pancreas or put out of business a heart transplant surgeon by restoring a heart. Will you commit to taking seriously the promise of regenerative medicine and stem cell medicines?"

Dr. Stephen Hahn, President Trump's nominee to lead the agency, replied that he would "certainly commit to that."

The number of stem cell clinics in the U.S. doubled every year from 2009 to 2014, according to a report in the journal Regenerative Medicine.

Major renowned medical centers such as the Mayo Clinic are researching stem cell therapies for conditions including arthritis and heart problems.

But as stem cell clinics not affiliated with medical centers proliferate, so have serious concerns. In 2017, the New England Journal of Medicine reported that three women were virtually blinded from unproven "stem cell" treatments that actually involved having fat injected into their eyes.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

That has brought increased scrutiny from the FDA, which in June won a court ruling allowing the agency to regulate treatments at the Florida clinic where the three women were harmed.

Stem cell products have only been approved for two uses by the agency: for blood cancers and certain immune disorders. That hasnt stopped some providers from claiming their stem cell treatments can "cure" a wide range of conditions, from macular degeneration to multiple sclerosis unapproved treatments that are not only not effective, but could pose serious health risks.

Stem cells are very young cells that can develop into specialized cells, such as blood cells, bone cells and brain cells. According to the FDA, stem cells have the potential to replace, repair, restore and regenerate other cells, and could possibly be used to treat a number of medical conditions.

The only stem cell-based products currently approved by the FDA consist of blood stem cells derived from umbilical cord blood. These products are usually used in patients with blood cancers, such as leukemia and immune disorders. For patients with blood cancers, for example, stem cells are used after chemotherapy to replenish the blood cells that were destroyed during the treatment.

However, other uses are being studied. There are currently more than 650 active clinical trials for stem cell procedures, looking at a myriad of conditions including kidney failure and Crohn's disease.

But the purpose of a clinical trial is to determine if a treatment works or if it's safe.

People should understand that they're trying something that could potentially have benefit, Dr. Peter Marks, FDA director of biologics, said. But we don't know that benefit is really there, which means that they should understand the risk.

We do our best to make sure people are safe when they're getting investigational products, Marks said. When a product is in a clinical trial, the FDA can monitor it to make sure its safe, he added.

For patients considering stem cell treatments, the FDA recommends asking a health care provider if the FDA has reviewed the treatment.

This also applies to stem cell treatments that use a person's own cells. You may be told that because these are your cells, the FDA does not need to review or approve the treatment. That is not true, according to the FDA website.

The FDA has given that road map on how to do it responsibly, said Dr. Shane Shapiro, medical director at the Mayo Clinics Regenerative Medicine Therapeutics Program in Jacksonville, Florida.

Shapiro also recommends going to a provider that has an expertise in the disease or injury that they are offering stem cell products to treat.

I think it is important to point out when we see a patient at Mayo, they are still seeing someone with the expertise of a physician that is a specialist in the disease they need help with, he said.

Follow NBC HEALTH on Twitter & Facebook.

Patrick Martin is an associate producer in the NBC News Health & Medical Unit.

Originally posted here:
Many stem cell clinics promise unapproved treatments: How to stay safe - NBC News

Partnership aims to accelerate cell and gene therapy – Harvard Gazette

MIT Provost Martin A. Schmidt said sharing the risk among several institutions will not only make possible work that would be difficult for a single institution to tackle, it will also encourage collaboration that accelerates the process of moving discoveries from lab to patient.

MIT researchers are developing innovative approaches to cell and gene therapy, designing new concepts for such biopharmaceutical medicines as well as new processes to manufacture these products and qualify them for clinical use, Schmidt said. A shared facility to de-risk this innovation, including production, will facilitate even stronger collaborations among local universities, hospitals, and companies and ultimately, such a facility can help speed impact and access for patients. MIT appreciates Harvards lead in convening exploration of this opportunity for the Commonwealth.

Richard McCullough, Harvards vice provost for research and professor of materials science and engineering, who also helped lead the project, said although the centers activity will revolve around science and manufacturing, its true focus will be on patients.

The centers overarching goal will be improving patient care, McCullough said. This would occur both by speeding access to the essential, modified cells that patients in clinical trials await, and by fostering discoveries through collaborations within the centers innovation space. The aim is that discoveries result in whole new treatments or improved application of existing treatments to provide relief to a wider universe of patients.

Organized as a private nonprofit, the center will be supported by more than $50 million pledged by its partners. It will be staffed by a team of at least 40, experienced in the latest cell-manufacturing techniques and trained in the use of the latest equipment. Among its goals is disseminating badly needed skills into the Boston life-sciences workforce.

We have to be sure that we are constantly feeding the industry with talented people who know the right things, so personally, I am very excited about education programs, Ligner said. Initiatives like [this center] are essential to advancing the industry because they help organizations build on one anothers advances. For example, the full potential of cell and gene therapies will only be realized if we collaborate to address challenges, such as manufacturing, improving access, accelerating innovation, tackling cost issues, and then sharing our learnings.

The new center emerged from conversations with state officials, including Gov. Charlie Baker and Attorney General Maura Healey, and industry sector leaders about ways to bolster Massachusetts preeminence in life science research and medical innovation. Those conversations sparked a two-year consultation process at the invitation of Garber and Harvard Corporation Senior Fellow Bill Lee, that was coordinated with state officials and included representatives from industry, academia, venture capital, area hospitals, and government.

Cell and gene therapies have the potential to revolutionize the global health system. Recently, in Sweden, the first patient received cell therapy outside of a clinical trial. Its the start of an incredible time in the industry and in human health.

Emmanuel Ligner, president and chief executive of GE Healthcare Life Sciences

Called the Massachusetts Life Sciences Strategies Group, members reached out to regional experts beginning in 2017to discover what fields they considered most important and how best to support them. Cell and gene therapy rose to the top because of the considerable excitement generated by activity already going on, its potential to help patients, and its high potential for future growth and innovation. Also important were the opportunities to spread the high cost of these technologies across multiple institutions and, while so doing, capture the collaborative power of housing each player in the development chain within a single facility.

The centers board of directors will be comprised of Harvard, MIT, and industry partners Fujifilm, Alexandria Real Estate Equities, and GE Healthcare Life Sciences. Other members will include Harvard-affiliated teaching hospitals Massachusetts General Hospital, Brigham and Womens Hospital, Beth Israel Deaconess Medical Center, Boston Childrens Hospital, and the Dana-Farber Cancer Institute; as well as the Commonwealth of Massachusetts and life-sciences company MilliporeSigma.

When you look at the constellation of players coming together, you really have the best universities and the best teaching hospitals and the best corporate players all supporting it, McGuire said, which I think is a great opportunity.

The facility intends to provide researchers and emerging companies outside the consortium with access to excess material, though organizers said they expect it to be in high demand by center partners.

The centers boost to the areas cell and gene therapy endeavors comes early enough that it should help maintain leadership over places like California and China, which have made clear their interest in life-science research, McGuire said.

I think getting this early mover advantage is going to be huge [in] developing the technology and the know-how and, ultimately, the intellectual property around it, McGuire said.

For Sharpe, the ultimate payoff will come from using cancer immunotherapys checkpoint blockade and other cell and gene therapies to save and improve lives.

We are seeing long-term benefits in some patients whove received checkpoint blockade, Sharpe said. There are patients who are more than a decade out and are melanoma-free. I think that it really has transformed patient care, quality of life, and longevity. So Im optimistic that the more we learn, the more were going to be able to do to help patients.

Sign up for daily emails to get the latest Harvardnews.

The rest is here:
Partnership aims to accelerate cell and gene therapy - Harvard Gazette

Prestigious NY Cancer Center Will Spend $3.7M To Study Bogus Cancer Treatment – Forbes

Reportage in a Chinese medicine practice in Lyon, France Acupuncture session. (Photo by: ... [+] BSIP/Universal Images Group via Getty Images)

Sometimes I'm not sure whether the best response to pseudoscience is to ignore it, or to patiently try to explain why it's wrong, or to get mad.

This week I'm mad.

My anger and frustration was triggered bya tweetfrom Memorial Sloan-Kettering's Integrative Medicine account, shown here:

Image captured by the author

For those who don't know,Memorial Sloan-Kettering Cancer Centeris one of the world's leading cancer centers, both for treatment and research. If you are diagnosed with cancer, MSK is one of the best places to go.

But not everything at MSK is world class. Unfortunately, they have an"integrative medicine"center that offers a mixture of therapies ranging from helpful to benign to useless. One of their biggest activities is acupuncture, which they claim offers a wide range of benefits to cancer patients.

The MSK tweet shown here was boasting abouta new, $3.7 million studyfunded by NIH to study the effect of acupuncture on pain that cancer patients experience from chemotherapy and bone-marrow transplants.

Here's why I'm mad: cancer patients are extremely vulnerable, often suffering the most frightening and difficult experience of their lives. They are completely dependent on medical experts to help them. When a place like MSK suggests a treatment, patients take it very seriouslyas they should. But they really have no choice: a cancer patient cannot easily look for a second opinion, or switch hospitals or doctors. Even if they have the money (and cancer treatment is extremely expensive), switching hospitals might involve a long interruption with no treatment, during which they could die, and it might also involve traveling far from their home.

Offering these patients ineffective treatments based on pseudoscienceand make no mistake, that's what acupuncture isis immoral. Now, I strongly suspect that the MSK's "integrative medicine" doctors sincerely believe that acupuncture works. Their director, Jun Mao, is clearly a true believer, as explained inthis profile of himon the MSK website. But that doesn't make it okay.

I've written about acupuncture many times before (here,here,here, andhere, for example), but let me explain afresh why it is nonsense.

Acupuncture is based on a pre-scientific notion, invented long before humans understood physiology, chemistry, neurology, or even basic physics, which posits that a mysterious life force, called "qi," flows through the body on energy lines called meridians. As explainedin this article by MSK's Jun Mao:

"According to traditional Chinese medicine ... interruption or obstruction of qi was believed to make one vulnerable to illness. The insertion of needles at specific meridian acupoints was thought to regulate the flow of qi, thus producing therapeutic benefit."

Today we know that none of this exists. There is no qi, and there are no meridians. In that same article, Jun Mao continued by admitting that

"the ideas of qi and meridians are inconsistent with the modern understanding of human anatomy and physiology."

And yet this is what they offer to patients at MSK.

Just to be certain, I readone of the latest studies from MSK, published early this year, which claims to show that acupuncture relieves nausea, drowsiness, and lack of appetite in multiple myeloma patients who were going through stem cell transplants.

It's a mess: totally unconvincing, and a textbook case of p-hacking (ordata dredging). The paper describes a very small study, with just 60 patients total, in which they measured literally dozens of possible outcomes: overall symptom score at 3 different time points, a different score at 3 time points, each of 13 symptoms individually, and more. I counted 24 different p-values, most of them not even close to significant, but they fixated on the 3 that reached statistical significance. The two groups of 30 patients weren't properly balanced: the sham acupuncture group started out with more severe symptoms according to their own scoring metric, andFigure 2in the paper makes it pretty clear that there was no genuine difference in the effects of real versus sham acupuncture.

But they got it published (in a mediocre journal), so now they point to it as "proof" that acupuncture works for cancer patients. This study, bad as it is, appears to be the basis of the $3.7 million NIH grant that they're now going to use, they say, in "a larger study in 300 patients to confirm these previous findings."

And there you go: the goal of the new study,according to the scientists themselves, is not to see if the treatment works, but to confirm their pre-existing belief that acupuncture works. Or, asone scientist remarked on Twitter, "they already have a result in mind, the whole wording of this suggests that they EXPECT a positive outcome. How did this get funded exactly?"

Good question.

So I'm mad. I'm mad that NIH is spending millions of dollars on yet another study of a quack treatment (acupuncture) that should have been abandoned decades ago, but that persists because people make money off it. (And, as others have explained in detail, acupuncture is actually a huge scam that former Chinese dictator Mao Zedong foisted on his own people, because he couldn't afford to offer them real medicine. For a good expos of Chairman Mao's scam,see this 2013 Slate piece.)

But I'm even more upset that doctors at one of the world's leading cancer centers are telling desperately ill patients, who trust them with their lives, that sticking needles into their bodies at bogus "acupuncture points" will relieve the pain and nausea of chemotherapy, or help them with other symptoms of cancer. I'm willing to bet that most MSK doctors don't believe any of this, but they don't want to invest the time or energy to try to stop it.

(I am somewhat reassured by the fact that MSK'sTwitter accounthas nearly 75,000 followers, while it's integrative medicine Twitter account has just 110.)

Or perhaps they are "shruggies": doctors who don't believe in nonsense, but figure it's probably harmless so they don't really object. To them I suggest this:read Dr. Val Jones's accountof how she too was a shruggie, until she realized that pseudoscience causes real harm.

And finally, let me point tothis study inJAMA Oncologyfrom last year,by doctors from Yale, which looked at the use of so-called complementary therapies among cancer patients. They found that

"Patients who received complementary medicine were more likely to refuse other conventional cancer treatment, and had a higher risk of death than no complementary medicine."

And also seethis 2017 studyfrom the Journal of the National Cancer Institute, which found that patients who used alternative medicine were 2.5 times more likely to die than patients who stuck to modern medical treatments.

That's right,Memorial Sloan-Kettering: patients who use non-traditional therapies are twice as likely to die. Thats why Im mad. This is not okay.

Read more here:
Prestigious NY Cancer Center Will Spend $3.7M To Study Bogus Cancer Treatment - Forbes

Buckley family thank community for support as thousands sign up to be a stem cell donor in three weeks – LeaderLive

A BUCKLEY family has thanked the community for their support as they continue to search for life-saving treatment.

Matt Davies, from Buckley, beat cancer last year but now has 12 months to live without a stem cell transplant.

The Leader previously reported that wife Sarah was urging people to register to be a stem cell donor, which is a small process that can save the lives of many.

In just three weeks, over 1,000 people signed up through Sarahs link to be on the register.

She was also told that just under 6,500 people had signed up in total within the space of the three weeks.

She told the Leader: We havent heard anything about a donor for Matt, we are still waiting. We have an appointment on Monday, so fingers crossed they give us an update.

I was really shocked when I saw the response. Its obviously something we are plugging every day because its so serious, but we didnt think wed get anywhere near that amount.

I didnt even think there would be one thousand. Its really, really good and the response on social media with people sending in messages of support has been great.

People are seeing our story published and its really nice they are reaching out and showing support, even people we dont know. Its not a nice situation to be in.

Matt was diagnosed with cancer last year and beat it, however less than eight months later after having his routine bone marrow results he was told the leukaemia was back and his only option was a stem cell transplant.

Without it, he would not be here in the next 12 months.

Sarah added: It doesnt go unnoticed. I know its not a big deal swabbing your mouth, but it is in the end, you could end up saving someones life.

I do thank everyone and hope we have a positive outcome from it all.

So far we havent had a match but thats why we keep going. We arent going to stop.

Over 800 was also recently raised at a charity event which included cake sales and a raffle. All proceeds were donated to the Christie in Manchester where Matt is receiving his treatment.

Sarah said they have not told their young children that the bug is back but it is likely Matt will spend Christmas in the Christie in Manchester.

She said: The whole community has come together to support us, even people we dont know and we really do appreciate it.

Its quite scary. You read these things but never think its going to be you or someone you know. You never think it would affect you but it can.

Everyone has been amazing. Those who havent already, please just register. It can take seconds and you may not ever be called but if you are, you can save someones life by swabbing your mouth and giving blood.

Those wishing to see if they are eligible to be a stem cell donor can do so online at http://www.dkms.org.uk.

Matts journey can also be followed via Facebook and Instagram page team_davies_.

Read the original here:
Buckley family thank community for support as thousands sign up to be a stem cell donor in three weeks - LeaderLive